2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Phase 2
1
Status
Terminated
1
Not yet recruiting
1
Completed
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Pain
5
Colorectal Neoplasms
5
Neoplasms
4
Breast Neoplasms
4
Stomatitis
3
Neoplasm Metastasis
3
Adenoma
3
Urologic Neoplasms
2
Stomach Neoplasms
2
Mucositis
2
Insulin Resistance
2
Head and Neck Neoplasms
2
Vulvodynia
1
Urologic Diseases
1
Urolithiasis
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Sleep Initiation and Maintenance Disorders
1
Skin Neoplasms
1
Rectal Neoplasms
1
Polycystic Ovary Syndrome
1
Pain, Postoperative
1
Non-Muscle Invasive Bladder Neoplasms
1
Multiple Myeloma
1
Multiple Endocrine Neoplasia Type 1
1
Mobility Limitation
1
Melanoma
1
MRSA Colonization
1
Interventions
pembrolizumab
156
Gemcitabine
140
Capecitabine
123
Paclitaxel
120
Fluorouracil
117
Oxaliplatin
110
Bevacizumab
106
Nivolumab
99
Leucovorin
97
Docetaxel
97
Cisplatin
89
Radiosurgery
88
Irinotecan
87
Carboplatin
85
Cetuximab
72
Cyclophosphamide
71
Magnetic Resonance Spectroscopy
68
Specimen Handling
60
Radiotherapy
60
Trastuzumab
59
Biopsy
59
Ipilimumab
53
Drug Therapy
51
Everolimus
48
Pemetrexed
46
Albumin-Bound Paclitaxel
45
130-nm albumin-bound paclitaxel
44
Doxorubicin
42
Fulvestrant
40
aldesleukin
37
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
Water
×
Clear all
NCT07321847
2026-01-07
INJECTABL-3
Immunophotonics, Inc.
Phase 2/3
Not yet recruiting
717 enrolled
NCT04799249
2024-08-01
PRESERVE 2
G1 Therapeutics, Inc.
Phase 3
Completed
194 enrolled
NCT04863248
2023-04-14
PRESERVE 4
G1 Therapeutics, Inc.
Phase 2
Terminated
10 enrolled
14 charts